Early Impact of Nirsevimab on Ambulatory All-Cause Bronchiolitis: A Prospective Multicentric Surveillance Study in France.

Détails

Demande d'une copieDemande d'une copie
ID Serval
serval:BIB_D87442600A32
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
UNIL/CHUV
Titre
Early Impact of Nirsevimab on Ambulatory All-Cause Bronchiolitis: A Prospective Multicentric Surveillance Study in France.
Périodique
Journal of the Pediatric Infectious Diseases Society
Auteur⸱e⸱s
Levy C., Werner A., Rybak A., Béchet S., Batard C., Hassid F., Desandes R., Frandji B., Ouldali N., Cohen R.
ISSN
2048-7207 (Electronic)
ISSN-L
2048-7193
Statut éditorial
Publié
Date de publication
20/07/2024
Peer-reviewed
Oui
Volume
13
Numéro
7
Pages
371-373
Langue
anglais
Notes
Publication types: Multicenter Study ; Letter ; Journal Article
Publication Status: ppublish
Résumé
After implementation of nirsevimab in 2023 in France as compared with 2022-2023, we found a 52.7%, 95% CI [46.4-58.9]) decrease in all-cause bronchiolitis in children <3 months with the lowest number of bronchiolitis cases in this population since 2017.
Mots-clé
Humans, France, Prospective Studies, Bronchiolitis/drug therapy, Infant, Male, Female, Antibodies, Monoclonal, Humanized/therapeutic use, Antibodies, Monoclonal, Humanized/adverse effects, ambulatory, bronchiolitis, children, impact, nirsevimab
OAI-PMH
oai:serval.unil.ch:BIB_D87442600A32
DOI
10.1093/jpids/piae051
Pubmed
38779958
Web of science
001251774300001
Création de la notice
27/05/2024 13:52
Dernière modification de la notice
26/07/2024 6:02
Données d'usage